Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell 8Lymphoma, T-Cell, Cutaneous 6Lymphoma, Large-Cell, Anaplastic 5Lymphoma, T-Cell, Peripheral 4Mycosis Fungoides 3Lymphoma 3Immunoblastic Lymphadenopathy 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mesothelioma, Malignant 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Urethral Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 4venetoclax 3ruxolitinib 3Cytarabine 3Alemtuzumab 3itacitinib 2duvelisib 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Carmustine 2thymoglobulin 1romidepsin 1niraparib 1nelarabine 1letermovir 1ibrutinib 1Tacrolimus 1Sensitivity and Specificity 1Mitoxantrone 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × Depsipeptides × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡